Table 3 Incidence of grade 3/4 adverse events in a randomized study of rituximab plus CHOP versus CHOP alone in elderly patients with diffuse, large B cell lymphoma
From: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
| Regimen | ||
|---|---|---|
| Adverse event | CHOP | Rituximab + CHOP |
| Any grade 3/4 adverse event (including grade 2 infections) | 145 (74.0) | 159 (78.7) |
| Infections | ||
| Bronchitis | 16 (8.2) | 22 (10.9) |
| Urinary tract infection | 17 (8.7) | 19 (9.4) |
| Pneumonia | 13 (6.6) | 10 (5.0) |
| Febrile neutropenia | 47 (24.0) | 45 (22.3) |
| Respiratory disorders | ||
| Dyspnoea | 6 (3.1) | 16 (7.9) |
| Cough | 6 (3.1) | 8 (4.0) |
| Rhinitis | 5 (2.6) | 1 (0.5) |
| General disorders and administration site disorders | ||
| Pyrexia | 32 (16.3) | 26 (12.9) |
| Fatigue | 13 (6.6) | 8 (4.0) |
| General physical health deterioration | 10 (5.1) | 10 (5.0) |
| Gastrointestinal disorders | ||
| Vomiting | 12 (6.1) | 8 (4.0) |
| Abdominal pain | 7 (3.6) | 12 (5.9) |
